Company intelligence / Profile preview
Micro CRISPR
Vapi, Indiamicrocrispr.bio ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 1
01
Overview
Completed animal trials for MyCART (CAR T-cell therapy) and received approval for human trials. Currently enrolling patients for Phase 1 clinical trials, expected to complete in 12 months with commercial launch anticipated in 12-24 months (as of March 2025).
- Therapeutic areas
- OncologyHematology
- Modalities
- Cell therapyGene therapyCAR T-cell therapy
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Cancer hospitals across India for clinical trials
Beyond the preview
Go deeper on Micro CRISPR.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Micro CRISPR.